Victor Navas moreno

Dr. Victor Navas moreno


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VMVictor Navas moreno
Victor Navas moreno
FSFernando Sebastian-Valles
Fernando Sebastian-Valles
MVMarcos Lahera Vargas
Marcos Lahera Vargas
BMBerta Hernández Marín
Berta Hernández Marín
ELElena Carrillo López
Elena Carrillo López
JNJosé Luis Muñoz de Nova
José Luis Muñoz de Nova
Although the focus in the last decades has been on the overdiagnosis of incidentally detected thyroid carcinomas in early stages, the other extreme of the disease is represented by locally advanced tumors with the invasion of neighboring structures. These are infrequent tumors, but they have a high complexity and a poor prognosis. In the absence of effective therapies allowing preoperative tumor reduction, in order to achieve a more restricted surgery, treatment was limited to aggressive surgery with resection of the aerodigestive tract and major vascular structures or palliative treatment. However, due to the increased knowledge of tumor biology and the results that tyrosine kinase inhibitors have achieved in the treatment of radioactive iodine-refractory tumors, neoadjuvant therapy with a curative intent has emerged as a reality to be taken into account when dealing with these patients. This paper presents a narrative review of the current scientific evidence regarding neoadjuvant treatment in locally advanced thyroid cancer.

Verified
Journal Article
Open access
PDF file
VMVictor Navas moreno
Victor Navas moreno
FSFernando Sebastian-Valles
Fernando Sebastian-Valles
ELElena Carrillo López
Elena Carrillo López
AEAlicia Justel Enriquez
Alicia Justel Enriquez
CGCarolina Sager La Ganga
Carolina Sager La Ganga
Mónica Marazuela AzpirozMónica Marazuela Azpiroz
Mónica Marazuela Azpiroz
Objective: The use of transcatheter aortic valve implantation (TAVI) has expanded in patients with severe aortic stenosis who are deemed inoperable. However, sarcopenia may be a determining factor in their survival. The aim of our study is to assess the impact of sarcopenia, evaluated by computed tomography (CT), on mortality in this patient population. Methods: Patients with severe aortic stenosis undergoing follow-up after TAVI at Hospital Universitario de la Princesa were recruited. Body composition was analyzed using routine CT scans and open-source software. Survival analysis was performed, and correlations between body composition parameters at the T12 and L3 vertebral levels were assessed. Results: Our sample comprised 97 subjects. Time to mortality was associated with diabetes mellitus (p = 0.050), atrial fibrillation (p = 0.02), and respiratory disease (p = 0.03). Interestingly, sarcopenia (p = 0.039) and normal-density muscle area (p = 0.025) were also associated with time to mortality, with the association between sarcopenia and time to mortality becoming stronger after adjusting for covariates (p < 0.001). The correlation between different body composition parameters at the T12 and L3 vertebral levels was substantial and statistically significant. Conclusions: The use of CT to assess sarcopenia in patients with severe aortic stenosis undergoing TAVI is highly valuable and can predict time to mortality. Sarcopenia should be considered as a relevant parameter in the comprehensive evaluation of these patients.